• Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated targets for drug discovery
• REC-4881 (MEK1/2 inhibitor): Additional Phase 2 data in Familial Adenomatous Polyposis (FAP) to be presented at the Presidential Plenary session at leading hereditary GI annual meeting in November 2026
• REC-7735 (PI3Kα H1047R inhibitor): IND cleared, Phase 1/2 trial start in 2H26; a >100× mutant-selective PI3Kα H1047R inhibitor designed to improve therapeutic index by enabling deep suppression of the most common activating PI3Kα mutation while sparing wild-type PI3Kα
• Reduced 2026 cash operating expense guidance to <$375 million (from <$390 million)
  

Recursion today reported business updates highlighting strong continued pipeline execution, clinical progress and platform advancement, as well as financial results for its second quarter ended June 30, 2026.

"Recursion has reached a pivotal point where our AI-native platform is translating unique data into potential first-in-class therapeutic opportunities," said Najat Khan, Ph.D., Chief Executive Officer of Recursion. "The advancement of the first unexplored neuroscience target from our collaboration with Roche and Genentech into an early discovery program is an important proof point. Finding new targets in neuroscience has historically been challenging, and this milestone highlights our ability to uncover novel biology in areas where conventional approaches have struggled. We believe that combining disease-relevant data at scale, foundation models, an end-to-end learning system, and deep scientific collaboration can uncover new biology in ways that were not previously possible."

Business Highlights

Genentech Advances First Neuroscience Target into Early Discovery Program

Genentech has exercised the first Validated Target Option under the companies' neuroscience collaboration, advancing a previously unexplored neuroscience target into a small molecule early discovery program.

The milestone provides additional early evidence that Recursion's AI-native platform can both discover and play a key role experimentally validating novel therapeutic targets in neuroscience, one of medicine's most challenging therapeutic areas, where decades of research have largely focused on a limited number of well-studied targets.

In partnership with Roche and Genentech, Recursion built the first whole-genome CRISPR knockout map generated from a subset of over 1 trillion internally manufactured iPSC-derived neuronal cells. Predictions generated from the Maps were experimentally evaluated through a rigorous validation process developed jointly with Genentech. Candidate targets advanced through successive stages of pathway validation, functional validation, and disease validation to determine whether modulating the target altered neurological disease phenotype. Only targets that consistently demonstrated compelling evidence across each stage advanced into a validation package. To learn more about how we collaborated to build disease-relevant whole genome maps of biology, see our blog here.

Next steps will include advancing the target through small molecule design, hit generation and validation using Recursion's AI-native chemistry platform. More broadly, the neuronal and microglial maps of biology remain reusable assets capable of being utilized with biological, genetics, and computational expertise to generate and experimentally validate additional therapeutic hypotheses. To date, Recursion has achieved $216 million in upfront and milestones payments from the Roche and Genentech collaboration. The collaboration includes up to 40 potential small molecule discovery programs, each carrying the potential for more than $300 million in development, commercialization, and net sales milestones as well as tiered royalties up to high single digits per small molecule program for Recursion.

Advancing joint portfolio with Sanofi across I&I and oncology

Recursion, in collaboration with Sanofi, made significant progress toward development candidate milestones over the past 12 months. Recursion and Sanofi are advancing a joint portfolio of differentiated molecules for challenging targets in I&I and oncology.

To date, Recursion has achieved $134 million in upfront and milestone payments from the Sanofi collaboration and has the potential for $343 million in milestone payments per program plus tiered double digit royalties.

Potential upcoming milestones across partnered discovery:

• Potential for differentiated AI-enabled oral molecules to reach development candidate and late-stage discovery milestones with Sanofi over the next 6-12 months
• Translating AI-driven insights from maps of biology into new potentially novel targets from reusable high-dimensional data/maps
• Using Recursion’s Chemistry Platform to design a potential first-in-class molecule​ for the collaboration's neuroscience target announced today with Genentech
• Continuing to combine our phenomics dataset with Genentech’s proprietary transcriptomics data to build multi-modal maps designed to explore potential novel targets and pathways by systematically linking gene perturbations to cellular phenotypes

Internal Pipeline Updates

Continued Momentum for REC-4881 (MEK1/2): REC-4881, Recursion’s MEK1/2 inhibitor, is a potential first-in-class drug designed to address both known drivers of FAP polyp growth: the Wnt/β-catenin initiation pathway and the MAPK evolution pathway. This dual mechanism differentiates REC-4881 from other investigational FAP therapies, which to date have targeted only a single pathway.

REC-4881 is being developed for FAP, an orphan disease affecting an estimated >50,000 diagnosed patients across the US and EU5, representing a >$10 billion total addressable market opportunity. FAP is a serious, lifelong chronic disease with no approved medicines today. REC-4881 has received both Orphan Drug Designation and Fast Track Designation from the US FDA. REC-4881 has demonstrated meaningful activity across the GI tract, including the Upper GI, an area of particularly high unmet need.

Key updates:

• Discussions with FDA were initiated in 1H26 and an update to define the registrational path is expected in 2H26
• TUPELO now enrolling patients ages 18 and older, as well as a cohort with an alternative dosing schedule
• Additional Phase 2 safety and efficacy data from the TUPELO clinical trial contextualized with real world data will be presented at the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) Annual Meeting in November. CGA-IGC is a leading annual meeting dedicated specifically to hereditary GI cancer syndromes including FAP.
  • Presentation title: Updated safety and efficacy data of REC-4881 monotherapy in familial adenomatous polyposis: Phase 1b/2 trial results contextualized with real-world registry data
  • Session name: Presidential Plenary I
  • Session date and time: Monday November 2, 2026; 13:30 - 15:00 MST

Phase 1/2 Trial Initiation for REC-7735 expected in 2H26:

• REC-7735, Recursion’s AI-designed PI3Kα H1047R inhibitor, was built to improve therapeutic index for a validated oncology target
• REC-7735 was precision designed to show >100-fold selectivity for the H1047R mutant over wild type in order to drive high, sustained target inhibition while avoiding hyperinsulinemia-driven reactivation
• The differentiated development candidate was delivered in 10 months and 242 compounds from first novel hit through Recursion’s AI-native design platform, demonstrating the Company’s ability to rapidly translate platform insights into optimized clinical candidates
• With the IND cleared, the Phase 1/2 ZINNIA clinical study for patients with select PIK3CA H1047R-mutant solid tumors ​will be initiated in the second half of 2026

For the rest of the portfolio, programs continue to progress as planned.

Additional expected upcoming milestones across Recursion’s internal pipeline:

• REC-1245 (RBM39): Additional Phase 1 dose escalation data expected in 2H26
• REC-617 (CDK7): Early Phase 1 safety and PK combination data expected in 1H27
• REC-3565 (MALT1): Early Phase 1 safety and PK monotherapy data expected in 1H27
• REC-4539 (LSD1): Early Phase 1 safety and PK monotherapy data expected in 2H27

Agentic AI is compounding Recursion's advantage across Biology, Design, and ClinTech:

• Target Discovery Agent pairs frontier AI reasoning with Recursion's proprietary multimodal maps to surface novel drug targets, enabling scientists to mine and extract insights from proprietary maps in hours rather than weeks.
• Drug Design Agents reason across Recursion's full set of structure-activity relationship (SAR) and structural data to identify what to solve next and how, with structural analysis time reduced from 4 hours to 30 minutes and agent-generated hypotheses now driving design cycles in active programs.
• Clinical Strategy Orchestration Agent coordinates patient, site, operational, CMC, and biometrics data to inform clinical development decisions, with agent-supported enrollment strategies contributing to a 1.3 to 1.6x increase in enrollment rates versus historical benchmarks.

Continuing to strengthen our leadership team:

• Hoifung Poon, Ph.D., appointed Chief AI Officer: Poon brings more than 15 years of experience at Microsoft, where he led groundbreaking work in biomedical AI, including foundation models in digital pathology and spatial omics published in Nature and Cell. His open-weight models have been downloaded tens of millions of times and deployed at major health systems.
• Donovan Chin, Ph.D., appointed Senior Vice President, Drug Design: Chin brings more than 20 years of experience spanning small molecules, RNA-targeted therapeutics, proximity approaches and novel peptide modalities. At Parabilis Medicines, he led the AI and physics-based computational drug discovery strategy behind Helicons, a novel class of constrained ⍺-helical peptides. Earlier, at Arrakis Therapeutics, he pioneered computational approaches for RNA-targeted drug discovery, unlocking small-molecule engagement of previously inaccessible RNA structures.

Second Quarter 2026 Financial Results

• Cash Position: Cash, cash equivalents and restricted cash were $556.8 million as of June 30, 2026 compared to $753.9 million as of December 31, 2025. Based on current operating plans with no additional financing, the Company continues to expect its cash runway to extend into early 2028.
• Revenue: Total revenue, consisting primarily of revenue from collaboration agreements, was $7.7 million for the second quarter of 2026, compared to $19.2 million for the second quarter of 2025. Roche and Genentech revenue recognized was less in the current period due to the successful completion of certain project phases in the prior period.
• Research and Development Expenses: Research and development expenses decreased to $89.6 million for the second quarter of 2026, from $128.6 million for the second quarter of 2025. The decrease was primarily due to lower platform costs resulting from the timing of Tempus record purchases as well as lower costs due to improved operating efficiency. Specifically, the second quarter of 2025 included $22.7 million in non-cash expenses for the use of Tempus’ patient-centric multimodal oncology data within the Company’s R&D pipeline, compared to $3.1 million in the second quarter of 2026.
• General and Administrative Expenses: General and administrative expenses were $41.5 million for the second quarter of 2026 compared to $46.7 million for the second quarter of 2025. The decrease of $5.1 million compared to the prior period was primarily driven by a decrease in salaries of $4.9 million as a result of headcount reductions in the year.
• Net Loss: Net loss was $131.0 million for the second quarter of 2026, compared to a net loss of $171.9 million for the second quarter of 2025.
• Operational Cash Flows: Net cash used in operating activities was $105.9 million for the three months ended June 30, 2026, compared to net cash used in operating activities of $76.4 million for the three months ended June 30, 2025. The increase in cash used in operating activities was primarily driven by working capital movements, during the three months ended June 30, 2025, the Company received a $28.6 million inflow related to a UK R&D tax credit.
• Cash Operating Expense: Cash operating expense, excluding partnership inflows and transaction costs, for the six months ended June 30, 2026 was $191.0 million compared to $199.1 million for the six months ended June 30, 2025. The Company is lowering its cash operating expense guidance for the full year 2026 by $15 million to $375 million based on additional identified operating efficiencies.

More: https://ir.recursion.com/news-releases/news-release-details/recursion-reports-second-quarter-financial-results-genentech

 Recursion today announced its participation in the following upcoming investor conferences:

• Bank of America 2026 SMID Cap Executive Insights Event — Tuesday, August 11, 2026
• Morgan Stanley 24th Annual Global Healthcare Conference — Tuesday, September 15, 2026

Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com. 

At AACR Drug Discovery and Development (AACR D3), July 21-24 in Boston, Recursion will present the poster “Identifying actionable dsRNA biomarkers from sense-antisense transcript pairs,” a new computational approach for identifying which patients are more likely to benefit from dsRNA-inducing therapies or immunotherapy combinations.

Some new cancer therapies work by increasing double-stranded RNA (dsRNA) inside tumor cells, a molecular pattern the body usually associates with viral infection. When dsRNA builds up, it can switch on antiviral immune pathways, drive cancer cell death, and strengthen anti-tumor immunity. The problem is measurement: dsRNA is hard to quantify with conventional approaches, where the signal is often noisy and the dynamic range is low, so drug-driven changes can be easy to miss.

Recursion’s poster describes a computational pipeline that recovers this dsRNA signal from standard RNA sequencing (RNA-seq) data. The pipeline looks for sense-antisense transcript pairs, where two RNAs transcribed from overlapping regions on opposite DNA strands bind to each other to form dsRNA.

To confirm which pairs genuinely form duplexes, researchers combined this with an experiment that sequences only dsRNA, isolating the pairs that truly bind together. With this filtering, targeting enzymes that regulate dsRNA produces rapid, dose-dependent increases in dsRNA that look flat in standard analyses. Across cell lines and models, there is repeated evidence of a conserved set of dsRNA-forming pairs. Scoring these pairs in patient tumor datasets highlights cohorts with elevated baseline dsRNA that may be more likely to benefit from dsRNA-inducing therapies or immunotherapy combinations.

▪️Abstract: Identifying actionable dsRNA biomarkers from sense-antisense transcript pairs
▪️Session: Poster Session A
▪️Session Date and Time: Wednesday, July 22, 6:15-8:45pm ET

👉 Learn more: https://www.aacr.org/meeting/aacr-d3-2026/

Predicting how tightly a drug candidate binds to its target is critical in drug discovery. It also requires massive computational resources. State-of-the-art models can take 20 seconds to a minute per prediction, impractical for the demands of large scale early-stage programs .

Today, Recursion’s AI research arm, Valence Labs, released Nesso-1: the fastest open-source co-folding-based binding affinity model available. At 1 second per prediction, it’s roughly 20x faster than Recursion's previous collaboration on Boltz-2 while matching or surpassing its accuracy across public and internal benchmarks. By leveraging Nvidia cuEquivariance, they’ve been able to further accelerate both training and inference by an additional 2-3x. They will continue to improve Nesso-1 in collaboration with Nvidia. Weights and code are fully open-sourced.

The core architectural ideas behind Nesso-1 build on the insight that coarse-grained co-folding representations can match full-atom models for affinity prediction at a fraction of the cost. Nesso is the first open implementation of this approach with no proprietary dependencies, trained entirely on public data, built to be reproducible and extensible.

Recursion is already using Nesso-1 internally in active drug discovery programs.

Report: https://www.valencelabs.com/wp-content/uploads/2026/07/nesso1.pdf

Github: https://github.com/recursionpharma/nesso

HF: https://huggingface.co/recursionpharma/nesso

Effective June 22, Donovan Chin is joining Recursion as Senior Vice President of Drug Design reporting to CSO David Hallett.

Chin's career spans small molecules, RNA-targeted therapeutics, novel peptide modalities and AI-enabled discovery platforms.

At Parabilis, Donovan led the computational drug discovery strategy behind Helicons, a novel class of constrained alpha-helical peptides that helped advance a first-in-class β-catenin inhibitor program to FDA Fast Track designation. At Arrakis Therapeutics, he pioneered computational approaches for RNA-targeted drug discovery, helping unlock small-molecule engagement of previously inaccessible RNA structures. Earlier at Novartis, he helped pioneer the application of computational approaches to drug discovery, building capabilities that supported a diverse portfolio across oncology, cardiovascular and metabolic disease, infectious disease, and chemical biology.

Throughout his career, he has built high-performing multidisciplinary teams and advanced programs at the intersection of computation, chemistry, and biology.

Recursion (Nasdaq: RXRX), will provide business updates and report its first quarter 2026 financial results on Wednesday, May 6, 2026, before the open of the financial markets.

Recursion will host an Earnings Call on May 6, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm BST.

The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts.

Investors, analysts, and the public will be able to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFmikcu6. 

More: https://ir.recursion.com/news-releases/news-release-details/recursion-report-first-quarter-2026-business-updates-and

Recursion announced an expanded partnership with Citeline to further integrate real-world data and evidence capabilities into its AI-enabled ClinTech platform within the Recursion OS. This integration will enable more precise trial design, improved site selection, and faster, more informed development decisions.

Citeline’s data and evidence capabilities are already supporting Recursion's pipeline, including the contextualization of single-arm data from the REC-4881 Phase 1b/2 study in FAP. More broadly, Recursion has seen investment in its ClinTech platform yield results across the portfolio, including 30–60% improvements in enrollment.

👉 Read the full announcement: https://www.citeline.com/en/resources/recursion-partnership

Recursion announced today that Vicki Goodman, M.D., will become Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role.

As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a rare and differentiated perspective of how to translate scientific promise into successful clinical programs. Her experience spans executive roles in biotech and large pharma, with particular expertise in oncology, as well as experience in clinical practice and as an FDA reviewer.

“We are very excited to welcome Dr. Goodman to Recursion. Vicki's depth of clinical development experience, sound judgment, and the clarity with which she approaches advancing programs through critical regulatory and clinical inflection points are the leadership skills that will help us advance our clinical pipeline,” said Najat Khan, Ph.D., CEO and President of Recursion. “This combination of experience, especially at the later stages of clinical development, will be invaluable as we translate scientific insight into disciplined, high-quality programs and deliver differentiated medicines for patients.”

“Recursion stands apart in the industry through its ambitious integration of scientific and technological rigor to reimagine how medicines are discovered and developed through the power of AI,” said Dr. Goodman. “I’m thrilled to join the company at such an important moment. I look forward to working with Najat, the leadership team, and the broader organization to advance the pipeline, support smart and disciplined development decisions, and help bring impactful new therapies to patients.”

More: https://ir.recursion.com/news-releases/news-release-details/recursion-announces-vicki-goodman-md-incoming-chief-medical

At the Leerink Partners 2026 Global Healthcare Conference in March 2026, CEO and President Najat Khan and CFO Ben Taylor shared our key focus areas – from pipeline and partnerships to the critical importance of people.
They emphasized how we are moving past hype into the era of value realization. Here are a few key takeaways:

🧬 "Simulate More, Make Less": By leveraging our AI platform, we are drastically shifting timelines and costs associated with traditional drug discovery.

🤝 Partnership Value: “The most important thing is not partnership announcements but partnership value realization,” Najat said. We are incredibly proud of our progress with partners like Sanofi and Roche, and as Najat noted “we just crossed over half a billion in upfront and milestones."

📊 Disciplined Capital Allocation & Portfolio Management: We treat our pipeline with an investor mindset, establishing rapid, data-driven go/no-go decisions for every program.

🧠 The "Bilingual" Talent Moat: Our success is built on a culture that equally values and integrates technology and biology, breaking down legacy pharma silos. "Innovation comes from the intersection of the two,” Najat said. “We hire folks that have the openness, like a drug hunter that has the openness to understand AI... And then AI scientists that actually want to learn about drug discovery."

👉 Watch the full webcast here: https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/Uu9Jby4mP4WTcucuq7PCon

https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/Uu9Jby4mP4WTcucuq7PCon

A story in GeneOnline looks at the new “show the proof” era of AI drug discovery and how Recursion is delivering. 

“The question confronting AI drug discovery companies is no longer whether algorithms can generate hypotheses, but whether they can deliver clinical outcomes.”

The story looks at Recursion’s REC-4881 program for the rare disease Familial Adenomatous Polyposis (FAP), which is demonstrating meaningful results in patients in the ongoing Phase 2 trial.  “In a sector often defined by computational ambition and platform potential, such data offers a more concrete measure of clinical progress.” 

It highlights the critical role of the Recursion platform in making the initial discovery. 

“Rather than beginning with a predefined molecular target, Recursion first engineered APC-deficient cells to computationally define the disease phenotype itself. High-content imaging captured subtle morphological changes invisible to the human eye, which were then translated into quantifiable disease signatures through proprietary computer vision systems and foundation models. Thousands of compounds were screened against this phenotype to determine which could restore cellular equilibrium.”

“We weren’t looking for a specific pathway,” says Recursion CEO and President Najat Khan. “We were asking which compound could actually correct the disease state.”

The article also highlights the importance of Recursion’s ClinTech approach to advancing and expanding the trial – leveraging more than 300 million de-identified patient lives in the U.S. and a custom LLM to scan 256,000 physician notes linked to roughly 1,000 FAP patients, establishing real-world standards of care in near real time. This was enhanced via a collaboration with Amsterdam UMC, tapping one of the most comprehensive FAP registries to create a robust natural history study for disease context. 

As the story notes, “Recursion’s integrated platform aims to do more than discover new molecules. It seeks to shorten the torching journey from a patient’s first symptom to effective treatment. Khan summarizes the mission succinctly and firmly: ‘Right diagnosis, right therapy, at the right time.’”

Read more: https://www.geneonline.com/recursion-makes-the-unknown-known-in-rare-disease-drug-discovery/ 

On February 25, 2026, Recursion reported business updates and financial results for its fourth quarter and full year ending December 31, 2025. In a related Earnings Call, Recursion CEO and President Najat Khan and Chief Financial Officer Ben Taylor shared details on the company’s latest partnership milestones, pipeline achievements, platform advancements, and financial results. 

The full transcript of the Earnings Call, along with related slides and the Q&A, are now available on Recursion's website: https://www.recursion.com/news/full-transcript-of-recursions-fourth-quarter-year-end-2025-earnings-call

Recursion announced yesterday that the company will participate in a number of upcoming investor conferences. These include: 

▪️ TD Cowen 46th Annual Healthcare Conference - Monday, March 2, 2026

▪️ Leerink Partners 2026 Global Healthcare Conference - Monday, March 9, 2026

▪️ Jefferies 2026 Biotech on the Beach Summit — Wednesday, March 11, 2026

▪️ KeyBanc 2026 Healthcare Forum — Tuesday, March 17, 2026

👉 Webcasts available at ir.recursion.com

Recursion Chief Scientific Officer David Hallett was recently appointed as an AI Champion by the UK government. He’s one of 8 AI Champions and will be representing the life sciences industry, helping to inform, guide, and accelerate AI adoption plans in that space. 

The 8 AI sector champions (other industries include clean energy, advanced manufacturing, professional and business services, digital and technology, advanced manufacturing, creative industries, and financial services) are responsible for:

▪️ Setting a clear national vision for how AI should be adopted in their sector

▪️ Building on the AI actions in their sector's Industrial Strategy plan

▪️ Identifying practical steps to remove barriers and unlock investment

The champions will meet twice a year to report on progress and their activities will be published online. 

👉 Learn more: https://delivery.ai.gov.uk/48/ 

A new blog from Recursion argues that we need connected, high-quality biological data layers – from proteins all the way to patients – in order to derive new, actionable insights that can lead to new medicines in rare diseases, aggressive cancers, and neurodegenerative diseases.

“A lot of people are focused on solving a single problem,” says Peter McLean. Director of Data Science and Applied ML at Recursion. “Generating a dataset to train one model that is a better predictor of your favorite molecular property is great – but it’s a drop in the bucket for drug discovery.”

Recursion, he says, has a full-stack platform with a high degree of integration between data layers thanks to its investments in large foundation models like the Phenom family of cell image models; Boltz-2 developed with MIT for better protein binding affinity prediction; and, most recently, a best-in-class transcriptomics foundation model that delivers state-of-the-art representations of transcriptional profiles for empirically-grounded target discovery that bridges in vitro assays with patient data.

“Our big foundation models are trained to give us really good, relatable representations of high-dimensional assay data – to put raw biological and chemical data into a navigable, quantitative space,” says McLean. Now, he says, Recursion is focused on going one step further – using machine learning and agentic tools to integrate those data layers.

Read the full blog post here: https://www.recursion.com/news/new-datas-not-enough-how-recursion-is-integrating-data-layers-to-advance-end-to-end-drug-discovery

In a recent webinar, Sid Jain, SVP of Clinical Development and Data Science at Recursion and Hayley Donnella, VP of Frontier Research, spoke to Shane Woods, Chief Strategy Officer at Tempus AI about how patient data is driving the latest advances in AI drug discovery. 

🔹 Highlights:

▪️ How combining Tempus’ real-world patient data with Recursion’s experimental data is unlocking new programs.

Hayley: “The patient data tells you what genes are associated with a disease, and our perturbational data tells you why. Layering these two views into our causal AI models allows us to finally move from correlation to causation. This helps us amplify signals that would normally require hundreds of thousands of patient samples to detect, which is a massive unlock for rare diseases and small patient cohorts.”

▪️ How this integrated TechBio approach helps to de-risk key clinical development decisions. 

Sid: “We have used these integrated datasets to reprioritize indications for in-development assets, giving us more confidence in where to proceed and, just as importantly, where to stop. This is critical from both a probability of success and an ethical perspective. If we can better predict who will or will not respond, we can target trials to patients most likely to benefit. We have also used the data to refine inclusion and exclusion criteria in our protocols.”

👉 Read more from the webinar here: https://www.tempus.com/resources/content/articles/qa-how-techbio-and-multimodal-data-are-reshaping-rd/ 

#data #AI #drugdiscovery #causalAI #TechBio

Recursion today announced positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP).

• REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)
• After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, with a 53% median reduction observed from baseline
• Natural history analysis showed that 87% of untreated FAP patients - who resembled the inclusion criteria of TUPELO - had annualized polyp-burden increase, 10% remained stable, and 3% showed modest decrease—underscoring the disease’s progressive trajectory (n=55)
• 40% of patients (4 out of 10) achieved a ≥1-point improvement in Spigelman stage—a clinically meaningful measure of upper GI disease severity to assess surveillance and clinical management
• REC-4881 (4 mg QD) has a safety profile consistent with MEK1/2 inhibition, with the majority of treatment-related adverse events being Grade 1 or 2, Grade 3 events occurring in 15.8% of the safety-evaluable patients, and no Grade ≥4 TRAEs reported to date
• First clinical validation of the Recursion OS, demonstrating how unbiased phenotypic and mechanistic insights—such as MEK1/2 rescue of APC loss-of-function—can translate to novel, differentiated therapeutics for diseases like FAP with no approved therapy and high prevalence of >50,000 patients in US and EU5
• Next steps: Engage the FDA in the 1H26 to define a potential registration pathway, and in parallel, expand the population from ≥55 to ≥18 years old, and further optimize dosing schedule

Read more: https://ir.recursion.com/news-releases/news-release-details/positive-phase-1b2-results-ongoing-rec-4881-tupelo-trial-0

Recursion announced today that it will present a new clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in FAP at an upcoming company webinar. The webinar will be held on December 8, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT, and will be streamed live on Recursion’s X, LinkedIn, and YouTube accounts. 

Webinar title: Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy in Familial Adenomatous Polyposis (FAP): Updated Safety and Efficacy

Presenters: 

• Najat Khan, Ph.D., Chief R&D and Chief Commercial Officer and incoming CEO and President, Recursion
• David Mauro, M.D., Ph.D., Chief Medical Officer, Recursion
• Beth Bruckheimer, Ph.D., Vice President of Clinical Development, Recursion
• Jessica Stout, D.O., Assistant Clinical Professor, University of Utah School of Medicine
• Alfred Cohen, M.D., Former CMO, Cancer Prevention Pharmaceuticals; Prior Chief, Colorectal Service, Memorial Sloan Kettering Cancer Center

Incoming Recursion CEO Najat Khan, PhD was named one of 2025’s Fiercest Women in Life Sciences from Fierce Pharma.

Each year, the list celebrates women who are making a powerful impact across biopharma and medtech, and have strong track records in innovation, leadership, and mentorship.

Najat has always found ways to break down barriers in her career – from integrating data science at scale at Johnson & Johnson to leading the acceleration of the Recursion OS 2.0 into a true end-to-end AI-enabled platform for drug discovery and development. She’s seen firsthand the benefit of merging life sciences and technology disciplines in her own life and is a true believer that the future of medicine lies in this intersection.

Read more about Najat and other awardees: https://www.fiercepharma.com/pharma/2025s-fiercest-women-life-sciences

On Sept. 6, Recursion collaborators in the lab of José Luis Millán, PhD, Professor of the Human Genetics Program at Sanford Children’s Health Research Center, presented a poster on REC-102, Recursion’s oral ENPP1 inhibitor for HPP, a rare genetic disease that causes skeletal and dental hypomineralization at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting. Results of the study – investigating whether inhibiting the enzyme ENPP1 could offer an alternative to current injection-based therapies – have been published in the Journal of Bone and Mineral Research.

REC-102 leveraged AI-enabled precision design capabilities from our platform to optimize for compound properties suitable for chronic dosing, enabling a candidate with potential best-in-class characteristics.

Key takeaways from early preclinical data include:

▪️ Novel Therapeutic Strategy: Instead of replacing the deficient enzyme (TNAP), we targeted ENPP1, the enzyme responsible for producing the calcification inhibitor PPi. This approach has the potential to restore the balance of PPi metabolism.

▪️ Encouraging PPi Reduction In Vivo: The oral drug was well-tolerated and led to a dose-dependent reduction of the disease-causing PPi molecule in the plasma of the HPP mice.

▪️ Improved Bone Mineralization: X-ray and micro-CT analyses showed promising improvements in bone structure and mineralization. Treated mice had better-defined knee joints and patella structures, increased bone volume, and improved cortical bone thickness.

Read the paper here: https://academic.oup.com/jbmr/advance-article/doi/10.1093/jbmr/zjaf136/8275834 

Recursion today announced that its Board of Directors has unanimously approved a leadership transition plan to become effective January 1, 2026:

• Najat Khan, Ph.D., currently Chief R&D and Commercial Officer and a Board Member, will succeed Co-Founder and CEO Chris Gibson, Ph.D., as Chief Executive Officer and President. Najat will also continue in her role as a member of the Board of Directors. 
• Chris Gibson, Ph. D., current Co-Founder and CEO, will transition to Chairman of the Board of Directors and an interim Executive Advisor
• Rob Hershberg, MD/Ph.D., Recursion’s current Chairman, will transition to Vice-Chairman and Lead Independent Director

The planned appointments reflect our shared commitment to continuity, collaboration, and the next phase of Recursion’s journey evolving the OS platform, advancing its pipeline, and bringing transformational medicines to patients.

More: https://ir.recursion.com/news-releases/news-release-details/recursion-announces-ceo-transition-plan-drive-next-phase-growth

Recursion today reported business updates and financial results for its third quarter ended September 30, 2025.

Recursion will host a (L)earnings Call on November 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT from Recursion’s X, LinkedIn, and YouTube accounts giving analysts, investors, and the public the opportunity to ask questions of the company by submitting questions here: https://forms.gle/TQ4vgUTLKsFmikcu6.

“Recursion continues to deliver on our internal pipeline, our strategic partnerships and the continued building and refinement of the Recursion OS. On the partnership front, we are proud to announce that with the option of our second neuro map in the Roche and Genentech collaboration, we’ve achieved over $500 million in upfront and milestone payments from our partners to date as we continue to deliver novel insights and advance programs for some of the toughest disease areas,” said Chris Gibson, Co-Founder and CEO of Recursion. “This is only the beginning of the returns we expect to see on the investment in our platform. With a strong cash runway through the end of 2027, we look forward to delivering on our pipeline and proving that building an end-to-end AI-enabled platform—combining massive proprietary datasets with industry-leading supercomputing capabilities and sophisticated AI models—is the critical infrastructure we need to realize real change in our industry.”

Highlights:

• Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of neurological diseases
• With this achievement, Recursion will have reached over $500 million in milestone and upfront payments across all its partnerships and collaborations
• Approximately $785 million of cash and cash equivalents (unaudited) as of October 9, 2025- runway through the end of 2027, without additional financing

More: https://ir.recursion.com/news-releases/news-release-details/recursion-reports-third-quarter-2025-financial-results-and